A cancer pharmacogenomic screen powering crowd-sourced advancement of drug combination prediction

Abstract The effectiveness of most cancer targeted therapies is short lived since tumors evolve and develop resistance. Combinations of drugs offer the potential to overcome resistance, however the number of possible combinations is vast necessitating data-driven approaches to find optimal treatments tailored to a patient’s tumor. AstraZeneca carried out 11,576 experiments on 910 drug combinations across 85 cancer cell lines, recapitulating in vivo response profiles. These data, the largest openly available screen, were hosted by DREAM alongside deep molecular characterization from the Sanger Institute for a Challenge to computationally predict synergistic drug pairs and associated biomarkers. 160 teams participated to provide the most comprehensive methodological development and subsequent benchmarking to date. Winning methods incorporated prior knowledge of putative drug target interactions. For >60% of drug combinations synergy was reproducibly predicted with an accuracy matching biological replicate experiments, however 20% of drug combinations were poorly predicted by all methods. Genomic rationale for synergy predictions were identified, including antagonism unique to combined PIK3CB/D inhibition with the ADAM17 inhibitor where synergy is seen with other PI3K pathway inhibitors. All data, methods and code are freely available as a resource to the community.

[1]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[2]  Liang Xia,et al.  Functional analysis of 44 mutant androgen receptors from human prostate cancer. , 2002, Cancer research.

[3]  Adam A. Margolin,et al.  Reverse engineering cellular networks , 2006, Nature Protocols.

[4]  N. Kyprianou,et al.  Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. , 2008, Endocrine-related cancer.

[5]  Michael Chopp,et al.  ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation , 2009, Cancer biology & therapy.

[6]  Kai Ye,et al.  Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads , 2009, Bioinform..

[7]  Mariano J. Alvarez,et al.  A human B-cell interactome identifies MYB and FOXM1 as master regulators of proliferation in germinal centers , 2010, Molecular systems biology.

[8]  S. Swamy,et al.  PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data , 2009, Biostatistics.

[9]  C. López-Otín,et al.  The regulatory crosstalk between kinases and proteases in cancer , 2010, Nature Reviews Cancer.

[10]  Xiao Zhang,et al.  Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis , 2010, BMC Bioinformatics.

[11]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[12]  Sarat Chandarlapaty,et al.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.

[13]  B. Al-Lazikani,et al.  Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.

[14]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[15]  Mark Trifiro,et al.  The androgen receptor gene mutations database: 2012 update , 2012, Human mutation.

[16]  Diogo M. Camacho,et al.  Wisdom of crowds for robust gene network inference , 2012, Nature Methods.

[17]  Bertram Klinger,et al.  Supplementary Materials for : Network quantification of EGFR signaling unveils potential for targeted combination therapy , 2022 .

[18]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[19]  Dan Wang,et al.  Androgen receptor gene mutation, rearrangement, polymorphism , 2013, Translational andrology and urology.

[20]  Yuval Kluger,et al.  Ranking and combining multiple predictors without labeled data , 2013, Proceedings of the National Academy of Sciences.

[21]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds Citation , 2015 .

[22]  Joshua M. Korn,et al.  High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response , 2015, Nature Medicine.

[23]  Benjamin J. Raphael,et al.  Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.

[24]  Juancarlos Chan,et al.  Gene Ontology Consortium: going forward , 2014, Nucleic Acids Res..

[25]  Denis Thieffry,et al.  Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling , 2015, PLoS Comput. Biol..

[26]  C. Sander,et al.  Systematic identification of cancer driving signaling pathways based on mutual exclusivity of genomic alterations , 2014, Genome Biology.

[27]  Yuval Kluger,et al.  Estimating the accuracies of multiple classifiers without labeled data , 2014, AISTATS.

[28]  Simon T Barry,et al.  Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ. , 2015, Cancer cell.

[29]  James C. Chen,et al.  DIGGIT: a Bioconductor package to infer genetic variants driving cellular phenotypes , 2015, Bioinform..

[30]  Dennis Wang,et al.  Combenefit: an interactive platform for the analysis and visualization of drug combinations , 2016, Bioinform..

[31]  Zheng Rong Yang,et al.  Multi-omic measurement of mutually exclusive loss-of-function enriches for candidate synthetic lethal gene pairs , 2016, BMC Genomics.

[32]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[33]  Ping Chen,et al.  Interpreting transcriptional changes using causal graphs: new methods and their practical utility on public networks , 2016, BMC Bioinformatics.

[34]  Julio Saez-Rodriguez,et al.  Looking beyond the cancer cell for effective drug combinations , 2016, Genome Medicine.

[35]  Ying Sun,et al.  ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation. , 2016, International journal of oncology.

[36]  Yair Benita,et al.  An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies , 2016, Molecular Cancer Therapeutics.

[37]  Minoru Kanehisa,et al.  KEGG as a reference resource for gene and protein annotation , 2015, Nucleic Acids Res..

[38]  Julio Saez-Rodriguez,et al.  OmniPath: guidelines and gateway for literature-curated signaling pathway resources , 2016, Nature Methods.

[39]  Andreas Bender,et al.  Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. , 2016, Drug discovery today.

[40]  S. Friend,et al.  Crowdsourcing biomedical research: leveraging communities as innovation engines , 2016, Nature Reviews Genetics.

[41]  Juanita Lopez,et al.  Combine and conquer: challenges for targeted therapy combinations in early phase trials , 2017, Nature Reviews Clinical Oncology.

[42]  J. Fisher,et al.  Cell-Specific Computational Modeling of the PIM Pathway in Acute Myeloid Leukemia. , 2017, Cancer research.

[43]  Bertram Klinger,et al.  Drug Resistance Mechanisms in Colorectal Cancer Dissected with Cell Type-Specific Dynamic Logic Models. , 2017, Cancer research.

[44]  Peter K. Sorger,et al.  Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy , 2017, Cell.

[45]  Levi A Garraway,et al.  Adaptive resistance of melanoma cells to RAF inhibition via reversible induction of a slowly dividing de‐differentiated state , 2017, Molecular systems biology.

[46]  Larry Rubinstein,et al.  The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity. , 2017, Cancer research.

[47]  Saroja Ramanujan,et al.  Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model , 2017, npj Systems Biology and Applications.